Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04589403 · ClinicalTrials.gov registry record · Phase 1
1a/1b Study of OPT101 First in Human Study Assessing Safety and Tolerability of 15-mer Peptide.
A Phase 1 study, sponsored by Op-T.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT04589403 is a Phase 1 study that has completed, run by Op-T. The registered enrollment target is 14 participants.
The verdict
NCT04589403, a Phase 1 study, has completed, sponsored by Op-T.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
This is a first-in-human study, Phase 1, randomized, placebo-controlled, double blinded study that will be conducted in 2 parts.
Interventions
- DRUG OPT101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2021-02-18 |
| Est. Completion | 2021-09-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04589403
The ClinicalTrials.gov registry entry for NCT04589403 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Op-T, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which OPT101 is the first listed.
NCT04589403 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04589403 about?
NCT04589403 is a clinical study titled "1a/1b Study of OPT101 First in Human Study Assessing Safety and Tolerability of 15-mer Peptide.". This is a first-in-human study, Phase 1, randomized, placebo-controlled, double blinded study that will be conducted in 2 parts.
What is the current status of trial NCT04589403?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2021-02-18. Estimated completion is 2021-09-27.
What interventions are being tested in trial NCT04589403?
The interventions under investigation include: OPT101 (DRUG).
Who is sponsoring clinical trial NCT04589403?
This trial is sponsored by Op-T, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.